We are live on ! Find out more
VA

VR Adviser Portfolio holdings

AUM $2.68B
1-Year Est. Return 422.73%
This Fund
S&P 500
This Quarter Est. Return
+57.13%
1 Year Est. Return
+422.73%
3 Year Est. Return
+1,447.09%
5 Year Est. Return
+3,249.52%
10 Year Est. Return
–
AUM
$594M
AUM Growth
-$54.5M
Cap. Flow
-$79.3M
Cap. Flow %
-13.36%
Top 10 Hldgs %
70.57%
Holding
38
New
7
Increased
4
Reduced
6
Closed
10

Top Buys

Rank Stock Value
1
AXSM icon
Axsome Therapeutics
AXSM
+$40.1M
2
NVAX icon
Novavax
NVAX
+$33.2M
3
MRUS
Merus
MRUS
+$21.6M
4
CELC icon
Celcuity
CELC
+$21.6M
5
KALV
KalVista Pharmaceuticals
KALV
+$15.6M

Top Sells

Rank Stock Value
1
TCDA
Tricida, Inc. Common Stock
TCDA
+$94.8M
2
RLMD icon
Relmada Therapeutics
RLMD
+$56.2M
3
GOSS icon
Gossamer Bio
GOSS
+$20.9M
4
TIL icon
Instil Bio
TIL
+$19.9M
5
AKUS
Akouos Inc
AKUS
+$18.9M

Sector Composition

Rank Sector Weight
1 Healthcare 98.81%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ATYR
26
aTyr Pharma
ATYR
$47.6M
$2.57M 0.43%
1,171,436
-227,453
-16% -$536K
AFMD
27
DELISTED
Affimed
AFMD
$1.77M 0.3%
142,857
– –
RLYB icon
28
Rallybio
RLYB
$84.5M
$1.76M 0.3%
33,567
– –
ALT icon
29
Altimmune
ALT
$552M
– –
-369,306
Closed -$4.72M
CLDX icon
30
Celldex Therapeutics
CLDX
$2.99B
– –
-75,000
Closed -$2.11M
GOSS icon
31
Gossamer Bio
GOSS
$82.9M
– –
-1,747,000
Closed -$20.9M
IMCR icon
32
Immunocore
IMCR
$1.72B
– –
-94,605
Closed -$4.44M
RLMD icon
33
Relmada Therapeutics
RLMD
$557M
– –
-1,518,056
Closed -$56.2M
TIL icon
34
Instil Bio
TIL
$48.3M
– –
-205,289
Closed -$19.9M
VTYX
35
DELISTED
Ventyx Biosciences
VTYX
– –
-207,925
Closed -$7.26M
RXDX
36
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
– –
-121,663
Closed -$7.18M
TCDA
37
DELISTED
Tricida, Inc. Common Stock
TCDA
– –
-9,050,064
Closed -$94.8M
AKUS
38
DELISTED
Akouos Inc
AKUS
– –
-2,800,566
Closed -$18.9M
1
2

Similar funds

MMEA
Main Management ETF Advisors San Francisco, California $2.68B AUM 24.27% 1-Year Est. Return
WGI
Westwood Global Investments Boston, Massachusetts $2.68B AUM 76.4% 1-Year Est. Return
TCAM
Turtle Creek Asset Management Toronto, Ontario, Canada $2.67B AUM 0.64% 1-Year Est. Return
SFI
Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return
HC
Henshaw Capital Woburn, Massachusetts $2.7B AUM 29.67% 1-Year Est. Return
CI
Capital International Los Angeles, California $2.7B AUM 31.08% 1-Year Est. Return
PCA
Pallas Capital Advisors Braintree, Massachusetts $2.66B AUM 22.31% 1-Year Est. Return
LP
Longaeva Partners Chicago, Illinois $2.7B AUM 37.16% 1-Year Est. Return

VR Adviser's Q4 2022 Portfolio in Review

As of Q4 2022, VR Adviser held 38 positions worth $594M, down 8.4% from $648M the previous quarter. Its ten largest holdings account for 71% of the portfolio.

VR Adviser withdrew a net $79.3M in Q4 2022, closing 10 positions and reducing 6 holdings. Its most notable exit was Tricida, Inc. Common Stock, an estimated $94.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 97% a quarter earlier.

Against the trend, VR Adviser opened a new position in Axsome Therapeutics worth $51.7M.

  • VR Adviser's largest Q4 2022 buy was Axsome Therapeutics: 670,718 shares worth $51.7M.
  • VR Adviser added most to Viridian Therapeutics in Q4 2022, an estimated $13.1M increase.
  • VR Adviser's biggest Q4 2022 reduction was Marinus Pharmaceuticals, Inc, cutting an estimated $6.81M.
  • VR Adviser fully exited Tricida, Inc. Common Stock in Q4 2022, selling an estimated $94.8M.
  • VR Adviser's ten largest holdings make up 71% of its $594M portfolio in Q4 2022.
  • VR Adviser opened 7 new positions and closed 10 in Q4 2022.
  • VR Adviser's portfolio value fell 8.4% quarter-over-quarter to $594M.

Based on VR Adviser's 13F filing for Q4 2022, filed 14 Feb 2023.